Rovio Entertainment Corporation: Repurchase of own shares on 24 November 2022
Rovio Entertainment Oyj STOCK EXCHANGE RELEASE 24.11.2022 at 18.45 EET | |
Rovio Entertainment Corporation - Repurchase of own shares on 24.11.2022 | |
Rovio Entertainment Corporation | |
In the Nasdaq Helsinki | |
Date | 24.11.2022 |
Exchange transaction | BUY |
Share trading code | ROVIO |
Amount, shares | 25264 |
Average price/share, EUR | 6,081513 |
Total cost, EUR | 153643,34 |
Rovio now holds a total of 6 278 205 shares including the shares repurchased on 24.11.2022 | |
On behalf of Rovio Entertainment Corporation | |
OP Corporate Bank PLC |
Further information:
Timo Rahkonen, VP Investor Relations & Corporate Strategy
+358 40 730 3442
RovioIR@rovio.com
Distribution:
Nasdaq Helsinki Ltd
Key media
www.rovio.com
About Rovio:
Rovio Entertainment Corporation is a global mobile-first games company that creates, develops and publishes mobile games, which have been downloaded over 5 billion times. Rovio is best known for the global Angry Birds brand, which started as a popular mobile game in 2009, and has since evolved from games to various entertainment, animations and consumer products in brand licensing. Rovio has produced The Angry Birds Movie (2016), and it’s sequel, The Angry Birds Movie 2 was released in 2019. The company offers multiple mobile games and has seven games studios – two in Espoo (Finland), one in Stockholm (Sweden), Copenhagen (Denmark), Montreal and Toronto (Canada), as well as a subsidiary in Izmir (Turkey) called Ruby Games, which was acquired in 2021. Most of the employees are based in Finland where Rovio is headquartered. The company’s shares are listed on the main list of NASDAQ Helsinki stock exchange with the trading code ROVIO. (www.rovio.com)
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Handelsinvest opdaterer prospektet23.4.2024 11:22:23 CEST | pressemeddelelse
Investeringsforeningen Handelsinvest Vestergade 8-16 8600 Silkeborg Tlf. 8989 2500 handelsinvest@jyskeinvest.dk www.handelsinvest.dk Nasdaq Copenhagen A/S Nikolaj Plads 6 1007 København K23. april 2024 Opdatering af prospektet i Handelsinvest Investeringsforeningen Handelsinvest har opdateret prospektet. Der er sket følgende opdateringer/ændringer: Opdatering af data på bestyrelsesmedlemmer.Tilføjelse af ”under overflytning” og ”under fusion” i de afdelingsspecifikke afsnit.Opdatering af investeringsstrategien i afdeling Nordamerika.Sproglige tilpasninger m.m. Det opdaterede prospekt kan findes på www.handelsinvest.dk Med venlig hilsen Lone Mørch Henrik Kragh Bestyrelsesformand Director
CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit23.4.2024 11:00:00 CEST | Press release
ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts. The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy. Presentation Details Title: Unlocking Tumor Eradication with Antibody-MHC T Cell Engagers Presenter: Leonardo Borras, Chief Scientific Officer Date: April 23, 2024 About CDR-Life CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to
Planlagt suspension i Sparinvest SICAV23.4.2024 10:54:57 CEST | pressemeddelelse
København, April 23, 2024 (GLOBE NEWSWIRE) -- Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeEquitas EUR RLU0362354549SSIEEURREthical Global Value EUR RLU0362355355SSIEGVEURREuropean Value EUR RLU0264920413SSIEUVEURRGlobal Value EUR RLU0138501191SSIGVEURR Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller Christian Rye Holm, CRH@nykredit.dk. Med venlig hilsen ID-Sparinvest, Filial af Sparinvest S.A, Luxembourg Dirk Schulze
Planlagt suspension i Investeringsforeningen Sparinvest23.4.2024 10:52:33 CEST | pressemeddelelse
Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeMix Aktier KL ADK0010014778SPIMAKLAValue Aktier KL ADK0010079631SPIVAKLAValue Europa KL ADK0060032571SPIVEUKLAValue Emerging Markets KL ADK0010304856SPIVEMKLABæredygtige Aktier Akk. KL ADK0060012896SPIBDAAKKKLAINDEX Dow Jones Sustainability World KLDK0010297464SPIDJWKLINDEX Emerging Markets KLDK0060300762SPIEMIKLINDEX Europa Growth KLDK0010297548SPIEUGKLINDEX Europa Small Cap KLDK0010297621SPIEUCKLINDEX Europa Value KLDK0010297704SPIEUVKLBæredygtige Aktier KL ADK0061294048SPIBDAGlobale Fokusaktier KL ADK0061293826SPIGFAMix Maksimum Risiko KL ADK0061551892SPIMMRIABæredygtige Value Aktier KL ADK0061551546SPIBDVAAMix Lav Risiko KL ADK0060623189SPIMLRKLAMix Mellem Risiko KL ADK0060623262SPIMMRKLAMix Høj Risiko KL ADK0060623346SPIMHRKLAMix Minimum Risiko KL ADK0060914901SPIMIXMINRISKKLA Eventuelle spørgsmål vedrørende
Delårsrapport for perioden 1. januar - 31. marts 202423.4.2024 10:47:40 CEST | pressemeddelelse
Bestyrelsen for Tivoli A/S har den 23. april 2024 behandlet og godkendt delårsrapporten for perioden 1. januar - 31. marts 2024. Tivoli åbnede sommersæsonen 22. marts, hvilket er tidligere end sidste år hvor sæsonen åbnede 31. marts. Dette påvirker resultatet for perioden som i hovedtræk er: En nettoomsætning på 90,4 mio. kr. mod 61,8 mio. kr. sidste år (+46%).Et resultat før af- og nedskrivninger (EBITDA) på -84,2 mio. kr. mod -96,7 mio. kr. sidste år.Et resultat før skat på -112,4 mio. kr. mod -126,1 mio. kr. sidste år.Et besøgstal på 221.000 mod 47.000 sidste år (+470%). ”Tivoli fortsætter den positive udvikling, vi så i 2023. Første kvartal 2024 tegner sig for et resultat svarende til det forventede, med bedre gæstetal og økonomisk resultat, end samme periode i 2023. Vi går ind i sommersæsonen med optimisme og en lang række attraktive tilbud til Tivolis gæster, som bl.a. kan se frem til en sommer med et overordentlig stærkt kulturprogram.” udtaler adm. direktør, Susanne Mørch Koch